Hematology/oncology clinics of North America
-
Hematol. Oncol. Clin. North Am. · Apr 1994
ReviewTopoisomerase I inhibitors. An overview of the camptothecin analogs.
The topoisomerase I inhibitors are an exciting new class of antineoplastic agents currently under clinical development. Analogues of camptothecin with improved toxicity profiles and antitumor activity included CPT-11 and topotecan. ⋯ Early results with topotecan against ovarian and lung cancer are also encouraging. Combination trials with other antineoplastic agents including cisplatin and etoposide, and early clinical trials with new topoisomerase I inhibitors, such as 9-aminocamptothecin, are underway.